This U.S. application will become the latest patent to issue in Aclaris’ JAK inhibitor drug development program for hair loss disorders.
The allowance of this U.S. application follows closely on the heels of the issuance of Japanese Letters Patent No. 6212107, which is directed to topical compositions of tofacitinib, as well as pharmaceutical compositions of tofacitinib as the sole therapeutic active agent, for treating hair loss disorders and for inducing hair growth. Japanese Letters Patent No. 6212107 was issued on
Another patent has already been issued in
“We are delighted with the steady expansion of the patent portfolio we exclusively licensed from
Through exclusive licenses, Aclaris has built an extensive intellectual property estate consisting of selective JAK 1/3 compounds, highly selective JAK 3 compounds, and methods of using JAK inhibitors to treat AA, AGA, and various other hair loss disorders. Aclaris has exclusively licensed a patent portfolio from
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe,” “expect,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Aclaris’ current beliefs and expectations. These forward-looking statements include expectations regarding the development of Aclaris’ product candidates focused on JAK inhibition for the treatment of hair loss disorders, including Aclaris’ intellectual property strategy. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Aclaris’ reliance on third parties over which it may not always have full control, risks associated with maintaining its intellectual property portfolio and other risks and uncertainties that are described in Aclaris’ Annual Report on Form 10-K for the year ended
Source: Aclaris Therapeutics, Inc.